LOGIN  |  REGISTER
Cue Biopharma
Astria Therapeutics

Modivcare to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 22, 2022 | Last Trade: US$24.91 0.95 3.96

Modivcare Inc., (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced that Heath Sampson, Modivcare’s President and Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2023 at 8:15 a.m. PST. Management will also host investor meetings throughout the day.

A link to the live webcast of the Company’s presentation can be found on Modivcare’s Investor Relations website at Modivcare Inc. - Investor Overview. A replay of the presentation will be available for 30 days following the date of the presentation.

About Modivcare

Modivcare Inc. (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their members. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal care and remote patient monitoring. To learn more about Modivcare, please visit www.modivcare.com.

Astria Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB